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Abstract Resistance to chemotherapy agents is a major chal-
lenge infront of cancer patient treatment and researchers. It is
known that several factors, such as multidrug resistance pro-
teins and ATP-binding cassette families, are cell membrane
transporters that can efflux several substrates such as chemo-
therapy agents from the cell cytoplasm. To reduce the adverse
effects of chemotherapy agents, various targeted-based cancer
therapy (TBCT) agents have been developed. TBCT has rev-
olutionized cancer treatment, and several agents have shown
more specific effects on tumor cells than chemotherapies.
Small molecule inhibitors and monoclonal antibodies are spe-
cific agents that mostly target tumor cells but have low side
effects on normal cells. Although these agents have been very
useful for cancer treatment, however, the presence of natural
and acquired resistance has blunted the advantages of targeted
therapies. Therefore, development of new options might be
necessary. A better understanding of tumor cell resistance
mechanisms to current treatment agents may provide an ap-
propriate platform for developing and improving new treat-
ment modalities. Therefore, in this review, different mecha-
nisms of tumor cell resistance to chemotherapy drugs and
current targeted therapies have been described.
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Introduction
After cardiovascular diseases, cancer is the second common
cause of death, which is demonstrated by massive cell prolif-
eration and cell death defects. Cancer is initiated by various
factors, such as impairment and mutations of tumor suppres-
sor genes and proteins [1].
For several years, chemotherapy has been one of the main
anti-cancer treatments. Chemotherapy agents inhibit the rap-
idly dividing cancer and normal cells (e.g., hair follicles, bone
marrow, and gastrointestinal cells). In addition to sever effects
of chemotherapy agents, drug resistance develops after treat-
ment regimens [2]. Therefore, development of new modalities
such as targeted-based cancer therapy (TBCT) agents is
necessary [3–5].
TBCT is a major and hot research topic in cancer treatment
field and currently the US Food and Drug Administration
(FDA), European Medical Agency (EMA) and other authori-
ties in different countries are evaluating and approving various
agents, including small molecule inhibitors (SMIs) and
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monoclonal antibodies (mAb) [6]. These agents target specific
molecules and block biologic transduction pathways, which
have been overexpressed or hyperactivated, respectively, by
tumor cells. However, consistent findings have indicated that
similar to chemotherapy, drug resistance to TBCTappeared in
most patients [1, 7, 8].
Resistance to cancer target therapies is divided into intrin-
sic (primary, first-line, or natural) and acquired (secondary,
second-line) resistances that are due to the natural factors exist
before treatments or are secondary to drug treatments,
respectively [9].
During and after treatment, tumorigenic cells exist, but they
are not able to produce another tumor population due to the
pressure of drugs [10]. However, acquisition of various muta-
tions, such as single nucleotide polymorphisms (SNPs) in tar-
get molecule [11], crosstalk between signaling pathways,
presence of tumor subpopulation cells, such as cancer stem
cells (CSCs) [9, 10, 12], and dysregulation of DNA damage
repair proteins that appear during or after treatment are the
most important reasons for resistance to therapy (Tables 1
and 2) [13, 14].
Several studies suggested that using multi-targeted thera-
pies, such as adenosine 3 phosphate (ATP)-competitive multi-
targeted inhibitors (type I SMIs) or mAbs, as well as long-term
therapy, may decrease the abundance of resistant tumor cells
or prevent drug resistance [5, 9, 15].Whether such approaches
are applicable or not need a better understanding of tumor
biology and the mechanisms underlying the tumor cell resis-
tance to current cancer drugs.
In this review, the most important mechanisms of drug
resistance in different tumors have been described. This article
tried to provide a clear picture of drug resistance mechanisms
for researchers and physicians to develop new treatment mo-
dalities or improve the treatment choices.
Types of drug resistance
Development of cancer drug resistance is the main reason for
poor prognosis of cancer as an incurable disease. Resistance to
the present therapies can be divided into two main categories,
including the intrinsic and acquired resistances [9]. Intrinsic
resistance exists naturally before any treatment; however, ac-
quired resistance develops during or after the treatment pro-
cess of malignant cells, which have been responsive to the
former treatments (Table 1) [16].
Intrinsic and acquired resistances have been shown for
most chemotherapy and targeted-therapy drugs in various
malignancies. It should be noted that some mechanisms of
drug resistance can be categorized in both natural and
acquired resistance. In the following sections, different
mechanisms of natural and acquired resistance have been
described.
Natural resistance factors
Several factors have been noted to contribute to natural resis-
tance. The presence of heterogeneous populations of tumor
cells, such as CSCs, changes in drug metabolism, expression
of drug resistance proteins in tumor cells, modified expression
of target protein, dysregulation of apoptosis, high activity of
DNA damage repair system, which is expressed by tumor
cells, bone marrow microenvironment, and steric hindrance
are among the most important factors that are involved in
resistance of cancer cells to treatment agents (Tables 1 and 2).
Heterogeneity of tumor cells before treatment
One of the major reasons for intrinsic/acquired drug resistance
is the presence of tumor subpopulation cells that are resistant
to different types of drugs and may arise during treatment
process (Fig. 1).
Previously, it was believed that tumors are the homogenous
population of dividing cells. However, this theory has been
replaced, and currently, it is known that cancers are consisting
of the heterogenic population of cells with a great degree of
genetic and phenotypic heterogeneity. In a given type of tu-
mor, cancer cells are heterogeneous, and various populations
of cells with several clonogenic potentials and capabilities
exist [16, 17]. These populations are consisted of major and
minor populations of tumor cells. During the treatment, the
major populations are usually destroyed by cancer drugs and
the minor resistant populations such as CSCs survive and
remain quiescent due to drug pressure. Based on different
conditions, such as the status of the immune system, age,
and hormones, these minor populations may start to repopu-
late and establish another tumor, which is resistant to the first-
line treatment [12].
Several kinds of research have shown that treatment failure
in several tumors has been attributed to the presence of CSCs
[16–19]. These cells are naturally extremely resistant to dif-
ferent therapeutic approaches (Fig. 1). Therefore, identifica-
tion and characterization of normal and CSCs are major re-
search areas of TBCT and have been described in the follow-
ing section.
Stem cells are a minor population of cells and have the
potential to differentiate into different types of cells. In several
tissues, they function as a type of repair system, dividing
without limit to repopulate other cells. Each new population
of cells (originated from stem cells) has the capacity either to
remain a stem cell or change to other types of more specialized
cells with a define function, such as a brain and muscle cells
[20, 21].
Two essential characteristics distinguished stem cells from
other cell types. First, they are undifferentiated cells with
renewing capacity (cell division) and might be inactive for a
long period. Second, they can differentiate and become a
10022 Tumor Biol. (2016) 37:10021–10039
tissue or an organ with specialized functions, when they acti-
vated under special conditions and environments. In several
organs and tissues, such as bone marrow, these cells frequent-
ly divide to repair and substitute damaged cells or tissues.
However, in other tissues, such as heart or pancreas, these
cells only divide under special situations [20, 22, 23].
Currently, differentiating normal stem cells from CSCs is
an important obstacle infront of researchers. Several investi-
gations have shown that normal and CSCs might have similar
differentiating marker profiles in the same tissues or organs.
For example, normal mammary stem cells, as well as tumor
cells in human breast cancer, have been shown to be CD24
negative [24, 25].
The presence of CSCs was initially described 20 years ago
for acute myeloid leukemia (AML), and it was shown that
these cells display the CD34+/CD38− phenotype and follow-
ing transplantation into severe combined immunodeficiency
(SCID) mice rise into tumor cells. Moreover, it was demon-
strated that a small population of breast CSCs has the pheno-
type of CD44+/CD24−/low/Lin− that were able to initiate tumor
formation when transplanted into non-obese diabetic (NOD)/
SCID mice [26, 27].
Epidermal normal stem cells, as well as tumorigenic cells,
are shown to be CD34+ in the chemically induced tumor of the
skin (squamous cell carcinomas) in the mouse [28]. Several
studies have described markers that differentiate normal and
CSCs in the same tissues [29, 30]. For example, CD26 has
been demonstrated to be expressed by CSCs and is expressed
in several types of cancer but not by normal stem cells.
Moreover, its expression correlates with CSCs properties,
such as the formation of new tumors, resistance to chemother-
apy, and the formation of spheres in vitro [31]. Moreover,
CD34+/CD38−/CD13−/CD33+/CD90+/CD123−/low/CD117+/
CD71+ phenotype has been described as the main phenotype
of normal hematopoietic stem cells [32].
As described before, CD34+/CD38−/Lin− phenotype was
the first that was described for leukemic stem cells in AML
[33]. However, further studies have shown more complicated
phenotype of CSCs. Several other markers, such as CD90,
CD71, CD123, CD117, HLA-DR [34], and CD26 for chronic
myeloid leukemia (CML) [35], CD33 for AML [36], and
CD133 for acute lymphocytic leukemia (ALL) [37] have been
suggested as CSC markers.
The presence of cisplatin-resistant cells (CD133+) has been
shown in non-small cell lung carcinoma (NSCLC) that also
express CXC chemokine receptor (CXCR) 4 [38]. Moreover,
several populations of highly quiescent cells that divide slow-
ly have been noted. Treatment with all-trans retinoic acid and
cisplatin has been effective on CD133+/CXCR4+ cells in
NSCLC [38].
The expression of CD133 and CXCR4 on CSCs has been
evaluated in ovarian cancer cell lines [39]. Several ovarian
cancer cell lines, such as OVCAR-3, -4, and -5 and colon
cancer cells, SW620 and HCT-116 express both markers.
Table 1 Mechanisms of
resistance to current targeted
therapies
Type Mechanism of resistance
Intrinsic
resistance
1 Heterogeneity of tumor cells before treatment
2 Cancer stem cells
3 Changes in drugmetabolism (increased efflux of drugs from tumor cell membrane) and drug
inactivation
4 Expression of drug resistance proteins
5 Extracellular vesicles
6 Low/overexpression of the target protein
7 Inefficient or dysregulation of apoptotic machinery
8 DNA damage repair
9 Bone marrow microenvironment
10 Steric hindrance
Acquired
resistance
1 Heterogeneity of tumor cells after treatment
2 Changes in drug targets: mutation and methylation
3 Mutations in the target gene after treatment
4 Hyperactivation of prosurvival signaling pathways
5 Up/downregulation of miRNAs
6 Crosstalk between intracellular signaling pathways
7 Chronopharmacology
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Table 2 Mechanisms of drug resistance to the current targeted-therapy agents
Name Trade name Selective target Resistant cancers Mechanism of resistance
(examples)
Afatinib Gilotrif HER2, EGFR, HER4 NSCLC, squamous cell
carcinoma of the head and
neck, breast cancer
Overexpression/mutation in
targets
Canertinib ND EGFR, HER2, HER4 Head and neck, breast, and
NSCLC, ovarian cancer
Overexpression/mutation in
targets
Cediranib Recentin VEGFR NSCLC, kidney and
colorectal cancer
Overexpression/mutation in
targets, CSCs
CP-673451 ND PDGFR NSCLC, colon carcinomas,
glioblastoma
Upregulation of alternative pro-
angiogenic signaling
pathways, CSCs,
overexpression of ABC
family
Crizotinib Xalkori MET NSCLC, anaplastic large cell
lymphoma,
neuroblastoma
Overexpression
Crenolanib ND FLT3, PDGFRα/β AML, gastrointestinal
stromal tumor, glioma
Mutation in targets
Cetuximab Erbitux EGFR Head and neck squamous
cell carcinoma, MCC
Mutation in targets
Dacomitinib ND EGFR NSCLC, gastric, head and
neck/glioma
Overexpression/mutation in
targets
Erlotinib Tarceva EGFR NSCLC, pancreatic cancer Overexpression/mutation in
targets,
chronopharmacology
Gefitinib Iressa EGFR NSCLC, AML Overexpression/mutation in
targets
Icotinib Conmana EGFR NSCLC Overexpression/mutation in
targets
KW-2449 ND FLT3 AML Mutation in targets
Lapatinib Tykerb HER-2, EGFR Breast cancer Overexpression/mutation in
targets, enhanced HER2
dimerization
Lenvatinib ND VEGFR2/3 Approved for thyroid cancer
in Japan
ABC transporters, CSCs
LY2801653 ND MET, RON NSCLC Activation of compensatory
signaling pathways
Neratinib HKI-272 EGFR, HER2 NSCLC, breast cancer Overexpression/mutation in
targets, enhanced HER2
dimerization
PD-173074 ND FGFR NSCLC, gastric carcinoma,
breast cancer
Mutation in targets
Quizartinib ND FLT3 AML Mutation in targets
R428 (BGB-324) ND AXL AML, NSCLC, breast cancer Reduced expression of miR-
34a
Tandutinib ND FLT3 RCC, CML Mutation in targets
Tivantinib Arqule MET RCC, breast cancer MET amplification
trastuzumab Herceptin (Herclon) HER2 Breast cancer, gastric
adenocarcinoma,
gastroesophageal junction
adenocarcinoma
Mutations, steric hindrance
Tivozanib AV-951 VEGFR1, 2, 3 RCC, breast cancer ABC transporters, CSCs
Vatalanib ND VEGFR2 NSCLC, DLBCL, colorectal
adenocarcinoma
CSCs
AZD8330 ND MEK1, 2 Multiple myeloma BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK activa-
tion
Binimetinib ND MEK1, 2 Metastatic melanoma BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK activa-
tion
Bosutinib Bosulif/SKI-606 SRC, BCR-ABL Ph+ CML Mutation in targets
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Table 2 (continued)
Name Trade name Selective target Resistant cancers Mechanism of resistance
(examples)
Buparlisib ND PI3Kα, β, δ, γ Multiple myeloma, head and
neck cancer, glioblastoma,
NSCLC
Activation of compensatory
signaling pathways
Cobimetinib ND MEK1, 2 Metastatic melanoma BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK
activation
Dasatinib Sprycel ABL, SRC, cKIT Ph+ CML and ALL Fixing the kinase domain in its
active configuration
Defactinib ND FAK Malignant pleural
mesothelioma, NSCLC,
ovarian cancer
ND
E6201 ND MEK1, 2 Melanoma, fallopian tube,
peritoneal cancer
BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK
activation
Entospletinib ND SYK AML, CLL ND
Fostamatinib ND SYK, P-gp T, B-cell lymphoma ND
GNF-5 ND BCR-ABL CML Mutation in target
Ibrutinib Imbruvica BTK CLL, MCL, DLBCL,
multiple myeloma
Mutation in target
Idelalisib Zydelig PI3Kδ CLL, indolent NHL, FL,
SLL
Upregulation or activation of
other PI3K isoforms
Imatinib Gleevec SRC, BCR-ABL ALL, CML, GIST Mutation in target
Lestaurtinib CEP-701 JAK2, FLT3, TrkAC,
VEGFR2, PKC
AML Mutation
Momelotinib ND JAK1–2 Multiple myeloma,
metastatic pancreatic
ductal adenocarcinoma,
NSCLC
Activation of compensatory
signaling pathways
NSC 74859 ND STAT3 Breast, prostate cancers ND
NVP-BYL719 ND PI3Kα Melanoma, head and neck
cancer
Upregulation or activation of
other PI3K isoforms
OPB-51602 ND STAT3 NHL, AML, ALL, CML ND
OPB-31121 ND STAT3 Multiple myeloma, Burkitt
lymphoma
ND
P505-15 ND SYK CLL ND
Pacritinib ND JAK2 AML, refractory CRC,
NSCLC, AML
ND
PD0325901 ND MEK1, 2 NSCLC, CRC, melanoma BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK
activation
PF-00562271 ND FAK NSCLC, ovarian cancer ND
Pictilisib ND PI3Kα, δ Prostate, breast cancers,
NSCLC
Upregulation or activation of
other PI3K isoforms
Pilaralisib ND PI3Kα, β, δ, γ Endometrial carcinoma,
breast cancer
Activation of compensatory
signaling pathways
Pimasertib ND MEK1, 2 Pancreatic, lung, ovarian
cancers
BRAF amplification and new
BRAF V600E splice
isoforms, BRAF-
independent MAPK
activation
Ponatinib Iclusig, Ariad BCR-ABL, SRC Ph+ CML and ALL, hepatic
biliary, small cell lung and
thyroid cancers
Mutation in target
Refametinib ND MEK1, 2 Hepatocellular carcinoma Activation of compensatory
signaling pathways
Ruxolitinib Jakafi and Jakavi JAK1, 2 Breast cancer, CML, AML,
NSCLC
Activation of compensatory
signaling pathways
Saracatinib ND SRC ND
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Moreover, octamer-binding transcription factor (OCT) 4, SRY
(sex determining region Y)-box (SOX) 2, kruppel-like factor
(KLF) 4, and NANOG were highly expressed in CD133+/
CXCR4+ OVCAR-5 cells, and these cells were determined
to be resistant to cisplatin in transplanted nude mice.
Moreover, primary ovarian cancer cells have been shown to
overexpress the ATP-binding cassette (ABC) sub-family G
member (ABCG) 2 drug transporter protein, CXCR4 and
CD133, and have been shown to have CSCs properties, in-
cluding chemoresistance and tumor development [39].
It has been considered that embryonic stem cells (ESC) and
CSCs have similar features, and it has been suggested that
common molecules such as transcription factors may exist
between ESCs and CSCs. SOX2 (SRY-related HMG-box
gene 2) was originally described to be associated with the
inhibition of neuronal cells differentiation and has been indi-
cated to acts as an essential transcriptional factor to sustain the
self-renewal ability of ESCs [40]. OCT4 (OCT3/4) is a mem-
ber of the POU domain transcription factor family and has
been shown to bind SOX2, which is the key regulator neces-
sary for the self-renewal and pluripotency of ESCs [41].
NANGO transcription factor is another molecule that is
expressed by CSCs and ESCs. It is a homeodomain protein
that sustains the pluripotency of ESCs by preventing nuclear
factor-κB (NF-κB) and collaborating with signal transducer
and activator of transcription (STAT) 3 transcription factor
[42]. It has been indicated that downregulation of these tran-
scription factors decreases the formation of tumor sphere and
prevents tumor establishment in xenograft models [43]. In
contrast, overexpression of these factors has been shown to
be related with poor tumor prognosis and metastasis in differ-
ent malignances, including gliomas, prostate and rectal can-
cers, gastric carcinoma, lung adenocarcinoma, and oral squa-
mous cell carcinoma [44].
CD133 has been also described as a marker of tumorigenic
cells in colon and brain tumors [20, 45, 46]. Although some
studies have verified these results, however, other reports have
suggested that this marker is not a common tumorigenic cells
marker [47–49].
The OCT4 is expressed in aggressive human hepato-
cellular carcinoma and its expression associates with CSC
markers [50]. Expression of SRY increased several stem
cell factors, such as CD13 and OCT4. It has been shown
that the promoter of OCT4 contained SRY-binding sites
and was directly activated by SRY. In hepatocellular car-
cinoma cells, SRY knockdown reduced OCT4 expression
and CSCs properties, such as chemoresistance, self-re-
newal, and tumorigenicity. However, overexpression of
OCT4 and SRY has been noted to promote CSC pheno-
types [50].
The expression of nestin (class VI intermediate filament)
protein was initially detected in neural stem cells during on-
togeny. Nestin expression has been reported in several tissues
in pathological conditions [51]. It is overexpressed during the
transformation of several human cancers, and the expression
is correlated with disease progression. The expression of
Table 2 (continued)
Name Trade name Selective target Resistant cancers Mechanism of resistance
(examples)
CRC, gastric, ovarian, small
cell lung and prostate
cancers, NSCLC
Selumetinib ND MEK1, 2 NSCLC, DLBCL, AML,
melanoma
Activation of compensatory
signaling pathways
Tofacitinib Xeljanz, Jakvinus JAK1–3 Breast cancer ND
Trametinib Mekinist MEK1, 2 Melanoma, CRC, NSCLC,
gastrointestinal cancer
Activation of compensatory
signaling pathways
ABT-199 Venetoclax BCL-2 CLL Mutations, impairment of
apoptosis
Vemurafenib Zelboraf BRAF Melanoma, thyroid cancer,
CRC
BRAF amplification and new
BRAF V600E splice
isoforms 2. BRAF-
independent MAPK
activation
HER human epidermal receptor, EGFR epidermal growth factor receptor, NSCLC non-small cells lung carcinoma, ND not defined, VEGFR vascular
endothelial growth factor receptor, CSCs cancer stem cells, PDGFR platelet-derived growth factor receptor, ABCATP-binding cassette, FLT3 FMS-like
tyrosine kinase 3, AML acute myeloid leukemia, FGFR fibroblast growth factor receptor, RCC renal cell carcinoma, CML chronic myeloid leukemia,
DLBCL diffused large B-cell lymphoma,MAPKmitogen-activated protein kinase, BCR B-cell receptor, PI3K phosphatidylinositol 3-kinase, ALL acute
lymphoid leukemia, FAK focal adhesion kinase, SYK spleen tyrosine kinase, CLL chronic lymphocytic leukemia, BTK Bruton tyrosine kinase, MCL
mantle cell lymphoma, NHL non-Hodgkin’s lymphoma, FL follicular lymphoma, SLL small lymphocytic lymphoma, GIST gastrointestinal stromal
tumors, JAK Janus kinase, PKC protein kinase C, STAT signal transducers and activators of transcription, CRC colorectal carcinoma, Ph+ Philadelphia
chromosome positive
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nestin together with other CSC markers was described to be
the phenotype of self-renewing cells in several cancers [51].
It has been shown that neural SCs and glioma SCs express
similar markers. Glioma SC markers are nestin+, CD15+, and
CD133+ [52]. Nestin is expressed during brain development
in glioma tissue. It is also expressed in 95.8% of glioma tumor
cells and is correlated with disease prognosis. The expression
of the nestin has been noted to be associated with poor disease
prognosis in malignant pleural mesothelioma [53]. Therefore,
it is mainly expressed in the invasive tumor cells that are
located at the peripheral side of tumor rather than tumor center
[54].
The surface receptor of hyaluronic acid, CD44, has been
suggested as a CSC marker in gastric cancer. Its expression
has been described to be associated with disease stage, tumor
size, lymph node metastasis, venous invasion, and lymphatic
invasion of gastric cancer cells [55].
Overall, while some studies have described similar stem
cell phenotype for both normal and CSCs, however, other
reports have suggested a few markers that differentiate CSCs
from normal stem cells. More investigation is necessary to
find specific surface or intracellular molecules (such as tran-
scription factors) to differentiate CSCs from their normal
counterparts.
On the other hand, current data strongly support the notion
that CSCs might be considered as the major players of drug
resistance, both to traditional chemotherapies and current
targeted-therapy agents and the specific targeting of these cells
might be a great step forward for cancer treatment.
Expression of drug resistance proteins and changes
in drug metabolism
Drug metabolism is one of the main reasons for drug
resistance. These factors include drug inactivation, ab-
sorption, distribution, and excretion. Tumor cell mem-
brane and special membrane-bound proteins are respon-
sible for drug efflux from the cells. Of several trans-
porters, the ABC and the solute carrier (SLC) as well
as xenobiotic metabolizing enzyme (XME) families are
the most important transmembrane proteins that drive
the transportation of many chemicals and drugs across
the cell membrane [9]. Most of these proteins eliminate
lipids from several kinds of hydrophobic drugs, includ-
ing alkylating agents (cyclophosphamide, chlorambucil,
lomustine, procarbazine), tyrosine kinase inhibitors
(TKIs) (moceranib, masitinib, imatinib, genistein), plati-
num compounds (cisplatin, carboplatin), antimetabolites
(gemcitabine, cytarabine, 5-fluorouracil, methotrexate),
topoisomerase I and II inhibitors (camptothecins,
indenoisoquinoline, mitoxantrone, doxorubicin), and mi-
crotubule inhibitors (vincristine, vinblastine, vinorelbine,
paclitaxel) [9, 56, 57].
Different phases of drug metabolism in the body can
change the efficacy of therapy on tumor cell growth. Several
types of intracellular enzymes, such as the (glutathione-S-
transferase(, (GST) family, cytochrome P450 (CYP) system,
and uridine diphospho-glucuronosyltransferase (UGT) family
are involved in drug metabolism inside the cells [58, 59].
First 
treatment
Initial tumor 
cell population
Tumor 
cells dead
Proliferation of resistant 
cells (e.g. CSC) and 
tumor recurrence
After treatment
Disease 
recurrence
2nd round of 
treatment and 
remission
Tumor
recurrence
Tumor
recurrence
Repeated treatments and remissions
v
Initial tumor cells 
Resistant tumor cells (e.g. CSC)
Mutated tumor cells (after 1st treatment) 
Mutated tumor cells (after 2nd treatment) 
Fig. 1 Schematic cartoon showing the presence of several tumor cells
populations. Each round of treatment destroys the sensitive cells;
however, mutated cells due to the pressure of treatments as well as
cancer stem cells (CSCs) survive and will start to grow in the proper time.
CSCs are a minor population and are the main resistant population that
will survive after treatments
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Several tumor types or specific populations within a tumor
overexpress specific glycoproteins in which they excrete
drugs from the cells and in a way, they neutralize the effects
of drugs [60, 61].
As described, among different proteins, ABC, SLC, and
XME molecules are the major types of drug transporters that
induce drug resistance. ABC transporters are divided into
three subtypes, including importers, exporters, and those
which are involved in DNA repair and translocation process
[62, 63].
Currently, more than 49 genes have been detected to en-
code the members of ABC transporter family, which are cat-
egorized into 7 sub-families (A to G). Several studies have
described the effects of gene polymorphisms on drug trans-
porters [64] and in ABC transporter family, more than 50
SNPs have been detected [65]. ABC sub-family B member
1 (ABCB1) and sub-family G member 2 (ABCG2), P-
glycoprotein (P-gp), breast cancer resistance protein
(BCRP), multidrug resistance protein 1 (MDR1), and
multidrug resistance-associated protein 1 (MRP1) are among
the most involved proteins in drug resistance [64].
Polymorphisms may change clinical outcomes through sever-
al mechanisms. The effectiveness of ABCB1 or ABCG2 func-
tion may increase through the decrease of binding to SMIs.
Moreover, transporters with dysfunctions may result in in-
creased toxicity due to changed transport of drugs from nor-
mal cells such as bone marrow cells. It has been shown that
synonymous SNPs in the ABCB1 change the reaction of the
drug with the transporter, due to changes in protein folding
[63].
SLC transporter system has 52 families and 362 different
genes [66]. Three families are the major players for cancer
drug efflux, including the organic anion transporting family
the SLC21 (SLCO), the SLC22 (the organic cation/anion/
zwitterion transporter family), and the SLC15 (the proton
oligopeptide cotransporter family).
XME enzymes are another family of enzymes in-
volved in biotransformation of anti-cancer drugs [60].
Cytochrome P-450 isoform families (18 families with
57 different isozymes), UDP glucuronosyltransferase
families (2 families with 16 isozymes) [67], and gluta-
thione S-transferases (6 families with 16 isozymes) [68]
are among the most prominent families. Other members
of this big family are aldo-keto reductases [69],
shor t cha in dehydrogenase or reduc tase [70] ,
carbonylreductase [71], alcohol dehydrogenase [72],
aldehyde dehydrogenase [73], xanthine/aldehyde oxidase
[74], nicotinamide adenine dinucleotide phosphate
(NADPH)-quinone oxidoreductase [], flavin-containing
monooxygenase [75], sulfotransferase [76], arylamine
N-acetyltransferase [], and epoxide hydrolase [77].
Activation of these proteins induces drug resistance in
tumor cells.
Due to the high number of the members in ABC, SLC, and
XME enzymes, these enzymes can specifically be involved in
the metabolism and inactivation of a broad range of cancer
drugs. For example, resistance to methotrexate in various leu-
kemias has been shown to be due to the decreased influx of
this drug that is mediated by the SLC19A1 enzyme, a member
of SLC family. Several genetic alterations such as point mu-
tations led to downregulation of SLC19A1 protein expression
and decreased the influx of anti-cancer drugs [61].
Extracellular vesicles and drug resistance
Extracellular vesicles (EVs) (such as exosomes and
microvesicles) are known as small particles (100–1000 nm)
that are surrounded by phospholipid bilayer similar to the cell
membrane. These vehicles are important organelles, involved
in various intercellular transportations (Fig. 2) [78]. One of the
major roles of these microvesicles is disseminating cancer
drug resistance to other non-resistant cancer cells.
Specifically, these organelles transfer different molecules in-
volved in resistance to other cells by shedding from resistant
cells and consequently induce drug resistance to non-resistant
cells. Several mediators, such as microRNAs (miRNAs)
(miR-100, miR-222, miR-30a, miR-34a, miR-145, miR-485-
3p, miR-1228, miR-1246, miR-1308, miR-149, miR-455-3p,
miR-638, miR-923, miR-1246, miR-23a, miR-1469, miR-
638, miR-1915, miR-2861) and drug efflux pumps (P-gp,
ABCG2, MRP1, ABCA3) are transported by these exosomes
or microvesicles and when they reached the recipient non-
resistant cell, they are fused and internalized by cells via
endocytic pathway [78].
In addition to the transfer of drug-resistant phenotype
to non-resistant cells, these organelles are directly in-
volved in the removal of cancer drugs from treated cells
[79, 80].
For example, doxorubicin and several SMIs have
been collected in these vesicles and are shed by tumor
cells after treatment [79]. It is suggested that the hydro-
phobic characteristics of some drugs may enhance their
interaction with lipid layer of vesicles and finally result
in drug elimination from the cells. Moreover, the pres-
ence of several drug transporters in these vesicles, such
as ATP7A/B and MRP2, increases the efflux of drugs
from cancer cells [78, 80]. The presence of drug-
resistant proteins has been shown in several malignan-
cies, such as P-gp in docetaxel-resistant prostate cancer
cells [81] and paclitaxel-resistant ovarian cancer cell
line [82], MRP1 transporter in ALL [83], ABCG2 in
doxorubicin-resistant breast cancer cells [84], and
ABCA3 in rituximab-resistant B-cell lymphoma cells
[85], which are responsible for induction of drug resis-
tance in these tumors [78].
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Modified expression of target protein
Several studies have noted the development of resistance to
cancer drugs due to over or low expression of target proteins
[86].
Post-treatment overexpression of the androgen receptor
gene has been described in around 30 % of recurrent prostate
cancer patients that were treated by castration; however, un-
treated prostate cancer patients did not show amplification of
androgen receptor [87].
It has been shown that the activity of B-cell receptor
(BCR)-ABL is required for development and transformation
of CML. Various inhibitors have been produced to target
BCR-ABL oncoprotein and have been tested in clinical trials
(herbimycin A and 2-phenylaminopyrimidine ST1571).
However, later researches showed the development of drug
resistance due to overexpression of BCR-ABL oncoprotein
[86].
Overexpression of IGF-1R has been shown to reduce the
inhibitory effects of trastuzumab on human epidermal receptor
(HER) 2-overexpressing breast cancer cells and induce resis-
tance of tumor cells to trastuzumab [88]. Blocking IGF-1 by
IGF-binding protein 3 (that inhibits the activation of IGF-1R)
restored the sensitivity of tumor cells to trastuzumab.
Moreover, in patients with lung cancer, amplification of
MET oncogene is one of the main mechanisms that lead to
acquired resistance to gefitinib and erlotinib [89].
Data show that decrease or increase expression of target
proteins by tumor cells, in several cases is associated with
tumor cells resistance, especially to targeted-therapy agents.
Dysregulation of apoptosis
Various cancer drugs may induce DNA impairment and in-
duce apoptosis and necrosis of tumor cells following the acti-
vation of the downstream apoptosis pathways (Fig. 2).
However, apoptosis deregulation of tumor cells has been as-
cribed as a major hallmark of cancer cells that failed the effects
of chemotherapeutic and targeted-therapy agents [90]. The
anti-apoptotic property of tumor cells is usually based on the
dysregulation (usually overexpression) of a few genes, such as
B-cell lymphoma (BCL)-2, myeloid cell leukemia (MCL)-1,
and tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL). Overexpression of the anti-apoptotic BCL-
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Fig. 2 A summary of various mechanisms of anti-cancer drug resistance. Mutations in drug target, activation of compensatory signaling pathways,
increase in DNA repair system, and overexpression of anti-apoptotic proteins are the major mechanisms of resistance
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2 protein has been shown to prevent mitochondria-associated
apoptosis pathway and prompts resistance to cancer agents
[91, 92]. Therefore, targeting upregulated molecules by
TBCT agents such as SMIs is an interesting approach to sen-
sitize tumor cells to targeted therapies (e.g., in combination
with other treatments). Targeting BCL-2 by SMIs is under
intensive investigation, and currently, FDA is evaluating
BCL-2 SMI, venetoclax (RG7601, GDC-0199/ABT-199) for
the treatment of relapsed or refractory chronic lymphocytic
leukemia (CLL) patients with 17p deletion.
TRAIL molecule has been known as an important factor in
apoptosis pathway and behaves as a ligand that induces the
process of apoptosis. Downregulation of TRAIL has been
shown to be associated with drug resistance in several malig-
nancies and to overcome drug resistance, induction of TRAIL
expression is a proper strategy [93–95]. Currently, three ther-
apeutic strategies have been described for activation of
TRAIL pathway, including the administration of TRAIL (re-
combinant form) (known as Apo2L/AMG951), using activat-
ing human anti-death receptor 4 (mapatumumab) or DR5
(lexatumumab) antibodies and delivery of the TRAIL coding
sequence in adenoviral (Ad) format into cancer cells (Ad5-
TRAIL). These methods are under investigation for inducing
apoptosis in tumor cells [56, 96].
Current data on targeting and activating apoptosis-inducing
proteins in tumor cells with dysregulated apoptotic proteins
are useful, and the combination of these agents with other
cytotoxic agents are promising and might confer a higher sur-
vival rate for cancer patients.
Repair of DNA damage
DNA damage repair is another mechanism that contributes to
induction of cancer drug resistance (Fig. 2). Many chemother-
apeutic agents, such as platinum drugs, topoisomerase inhib-
itors, and alkylating agents, induce DNA damage; however,
DNA damage repair machinery of tumor cells effectively in-
fluences the effects of DNA-damaging drugs [13].
A proper therapeutic approach is to inhibit DNA damage
repair system of malignant cells and thus different agents that
inhibit components of the DNA repair machinery have been
developed [14]. The most noticeable example of targeting
DNA damage repair is inhibitors of the DNA repair enzyme
poly-ADP-ribose polymerase (PARP). Several PARP inhibi-
tors have been produced and have shown promising effects.
Olaparib induces cell death in cancer cells with mutations in
the BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)
tumor suppressor genes. These genes are crucial for repair of
DNA double-strand breaks (homologous recombination).
Lack of repair of DNA double-strand breaks is usually com-
pensated by single-strand repair mechanisms that are depen-
dent on the function of PARP. Therefore, PARP inhibition
induces cell death due to the genetic instability in dividing
tumor cells [56].
The same as targeting anti-apoptosis proteins, the combi-
nation of drugs that target DNA repair machinery of tumor
cells with other cytotoxic agents may be useful to prevent anti-
cancer drug resistance.
Bone marrow microenvironment and drug resistance
Tumor cells located in bone marrow are usually more resistant
to cancer drugs than cells in peripheral blood (Fig. 2). Several
studies have described that the protection is afforded by se-
creted chemokines and expression of their ligands, such as
CXCL12 and CXCR4 in bone marrow environment and by
stromal cells that support tumor cells through cell to cell con-
tacts with tumor cells [97, 98] (Fig. 2).
For instance, inhibition of FMS-like tyrosine kinase-3
(FLT3) by inhibitors (e.g., FI-700) has shown good clinical
results in AML patients with FLT3 mutations; however, the
bone marrow tumor cell responses are frequently less than the
peripheral blood tumor cells. It has been shown by Kojima et
al. that protection is mediated via CXCL12/CXCR4 signaling
in the bone marrow [99].
To overcome the resistance of AML cells (with FLT3-
mutations) to SMIs, a combination of different types of
SMIs such as JAK inhibitors with FLT3 inhibitors has been
shown to override the effects of bone marrow stromal cell-
mediated resistance of AML cells [100].
In addition to bone marrow microenvironment, other fac-
tors such as cytokine/chemokine milieu might affect the sen-
sitivity of tumor cells to drugs. For example, exposure to plat-
inum doublets (cisplatin plus vinorelbine) has been described
to change the cytokine/chemokine microenvironment and the
phenotype of lung tumor cells, rendering them more sensitive
to cytotoxic T lymphocyte (CTL)-mediated lysis [101]. It has
been noted that exposure to platinum doublets significantly
reduced the protein secretion ratio of transforming growth
factor-β (TGF-β) to interleukin (IL)-8. Moreover, gene ex-
pression studies of two lung tumor cells in response to suble-
thal chemotherapy has shown the expression of 16 genes,
including those related to cytokine/chemokine and apoptotic
proteins as tumor necrosis factor-α (TNF-α), CXCL5, IL-8,
and B-cell lymphoma-2 (BCL-2) genes. These data may indi-
cate that sublethal doses of cisplatin/vinorelbine enhances the
sensitivity of tumor cells to perforin/granzyme-mediated CTL
killing thought modulation of tumor cells phenotype,
cytokine/chemokine milieu, and the ratio of pro-apoptotic to
anti-apoptotic proteins [101].
Steric hindrance and drug resistance
Steric hindrance is another mechanism of drug resistance. It is
demonstrated that overexpression of other molecules that
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surround the target protein inhibits the interaction of cancer
drugs with targeted protein [102]. For example, resistance of
tumor cells to trastuzumab has been described to be related to
high expression of MUC4 (a membrane-associated glycopro-
tein) in HER2-overexpressing cells. MUC4 has been shown to
bind to HER2 and inhibits binding of trastuzumab to HER2
through steric hindrance [103]. It is suggested thatMUC4may
be associated with cancer development due to the ability to
inhibit the recognition of tumor cells by the immune system
and prompt the metastasis and progression of cancer cells via
activation of HER2 and prevention of tumor cell apoptosis
[104]. Moreover, the mucinous subunit of MUC4 (ASGP-2)
binds to HER2 through the EGF-like region of HER2 [103]. It
has been proposed that MUC4 may increase the phosphory-
lation of HER2 on tyrosine residue 1248 [103], which increase
the transforming ability of HER2 [105]. Decreasing the ex-
pression ofMUC4 gene has been shown to increase the effects
of trastuzumab on MUC4 knockdown cells [106]. It is sug-
gested that MUC4 might hide epitopes of HER2 that bind to
trastuzumab and inhibits the binding of HER2 to antibody and
prevents the heterodimerization of HER2 with other epithelial
growth factor receptor (EGFR) members, such as HER3 and
EGFR, via steric hindrance that results in resistance of cells to
drug [106].
Therefore, downregulation or blocking the expression of
molecules involved in steric hindrance might be considered
as a proper strategy to overcome this type of resistance in
tumor cells.
Acquired resistance
Several factors, including tumor cell heterogeneity, changes in
drug targets, mutations after treatments, hyperactivation of
prosurvival signaling pathways, up/downregulation of specif-
ic microRNAs, crosstalk between survival signaling path-
ways, and chronopharmacology factors contribute to the de-
velopment of acquired resistance following tumor treatments
(Table 1, Figs. 1 and 2).
Tumor cell heterogeneity after treatment
As described in natural resistance factors, a tumor is typically
originated from a normal or non-cancerous cell, which un-
dergoes through several processes that are called tumorigenic
transformation. This transition is the result of different muta-
tions in the genome, which converted the origin normal cell to
an unusual tumor cell. Moreover, an established tumor is per-
sistent by several subpopulations of cells that are self-
renewing (CSC) and can generate tumorigenic cells [107,
108]. The heterogeneity of tumor cells has been described in
natural resistance section.
Changes in drug target in tumor cells: methylation
and mutations
Qualitative and quantitative modifications in drug targets are
critical mechanisms of drug resistance. These changes may be
quantitative, such as reduced or lost the expression of the drug
target, or may be induced by factors as inhibition of drug
binding to the targets by other proteins. These changes con-
tribute to both natural and acquired resistance. Induction of
mutation that modifies the structure of drug targets (genetic
alteration) is a qualitative factor that may change the affinity of
the drugs for their targets. Several types of these mutations
have been described in next section.
In addition to genetic alterations, other factors such as epi-
genetic factors might contribute to drug resistance. Epigenetic
modifications usually change the expression of target genes.
These alterations mostly comprise of covalent modifications
of DNA sequence and histone modifications that change gene
expression levels by methylation of gene promoter (at cyto-
sine residues by methyltransferase enzymes in the CpG
islands of gene promoter regions) or indirectly by changes in
chromatin packaging that regulate the availability of DNA to
special transcription factors. These modifications that induce
drug resistance are associated with dysregulation of apoptotic
factors and DNA repair enzymes as well as abnormal expres-
sion of drug efflux transporters [56].
Several studies have shown the association of these chang-
es with drug resistance. In DU145 prostate cancer cells, doce-
taxel and cabaxitaxel resistance (DU145 10DRCR) has been
described to be associatedwithDNAmethylation of cell-cycle
regulatory and pro-apoptotic genes [109]. Hypermethylation
of CpG island that silences DNA/RNA helicase Schlafen-11
(SLFN11) enzyme has been noted to be related to resistance to
chemotherapeutic agents such as platinum compounds [110].
Inhibition of DNA methylation using methylation inhibitor
decitabine (5-aza-2′-deoxycytidine or DAC) has been shown
to sensitize AML cells to the chemotherapy agent. Decitabine
is a DNA hypomethylating agent and induces differentiation
and apoptosis of AML leukemic cells to aclacinomycin
(ACLA) and cytarabine. Decitabine has described to decrease
the expression of DNA methyltransferase 1 (DNMT1) in
AML patients [111].
Several types of acquired mutations have been described
during the treatment of malignancies (Table 2).
Point mutations are very common and occur in dividing
tumor cells and are the most frequent mechanism of acquired
TKI resistance [112–114]. The most frequent type of point
mutations reduces the affinity of the target for the drug while
the enzyme catalytic activity may not change. The changes in
the amino acids near the enzyme binding site for the drug are
another type of mutations and reduce the accessibility of the
target region for the inhibitor binding [115]. Other point mu-
tations increase the affinity of the enzyme for ATP and
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decrease the effectiveness of the type I inhibitors (ATP com-
petitors) (Tables 1 and 2).
The best example of acquired resistance, due to mutations,
is CML patients, resistant to imatinib TKI that targets BCL-
ABL oncoprotein. CML patients constitutively express active
BCR-ABL. Imatinib prevents the activity of BCR-ABL by
binding to the inactive protein and inhibits autophosphoryla-
tion and activation of downstream signaling proteins [116].
However, the majority of patients in advanced or chronic
stages develop imatinib resistance [117]. More than 30 % of
the relapsed CML patients gain point mutations that are near
100 different point mutations. These mutations change the 3-
dimensional structure of the ABL kinase and abrogate the
ability of the imatinib to bind the ABL kinase [116, 118]. To
target the ABL mutants in imatinib-resistant patients, the sec-
ond generation of TKIs, such as nilotinib, dasatinib, bosutinib,
and sunitinib, were developed [119, 120]. These TKIs recog-
nize a distinct conformation of BCR-ABL and are proper for
imatinib-resistant patients. Dasatinib and nilotinib interact
with several mutants of ABL (imatinib-resistant); however,
these SMIs are not suitable for T315I (threonine to isoleucine
substitution at position 315) mutant form that modifies the
kinase and different contact points between the SMIs and the
protein kinase [121]. KW-2449 inhibitor has been developed
to inhibit T315I mutant form [122].
As a multi-targeted TKI, imatinib binds to the cKIT and
platelet-derived growth factor receptor (PDGFR). The kinase
is highly active in gastrointestinal stromal tumors (GIST)
[123]. However, the same as AML patients, more than 50 %
of GIST patients have been noted to develop mutation within
KIT gene that confers decreased affinity of imatinib to the
kinase [124]. To inhibit the activity of the mutants cKIT, su-
nitinib was produced; however, imatinib-resistant GIST pa-
tients developed resistance to this TKI [125].
Activating FLT3 mutations frequently happen in AML.
Treatment of AML patients with PKC412 (staurosporine de-
rivative) prevent FLT3 activity; however, several patients de-
veloped mutations in the FLT3 kinase region [126].
As previously described, sorafenib (multi-kinase inhibitor)
targets vascular endothelial growth factor receptor (VEGFR)
1-2, BRAF, PDGFR, cKIT, and FLT3 [4]. This TKI has
shown broad anti-tumoral activity. The combination of soraf-
enib with other TKIs has induced a variety of point mutations
in FLT3 [127], PDGFR [128], and BRAF [129] that confer
tumor resistance.
For the treatment of breast cancer patients, lapatinib is
a proper TKI and is approved by the FDA as an EGFR
inhibitor. It has been developed to suppress phosphory-
lation and downstream signaling of EGFR and HER2
[130]. Twelve mutations in the kinase region of HER2
have been shown to confer resistance to lapatinib [131].
In contrast to lapatinib, EXEL-7647 is active on all mu-
tant forms.
Other EGFR-TKIs, such as erlotinib and gefitinib, are
among the most widely investigated SMIs in NSCLC and
were approved by the FDA for the treatment of this cancer.
These SMIs are ATP-competitor TKIs and belong to the first
generation of selective EGFR-TKIs [4]. These TKIs are used
as the front-line targeted therapy for NSCLC patients with
EGFR mutations. However, the efficacy of these TKIs is
shown to be impeded by different mutations of EGFR mem-
bers. Mutations that activate the EGFR members, as the dele-
tion in exon 19 and L858R (leucine to arginine substitution at
position 858) point mutation, are the most frequent mutations,
and patients show good response to these two TKIs that in-
crease the kinase activity of EGFR members [3, 4]. However,
T790M missense mutation and insertions in exon 20 are early
genetic events that confer resistance to EGFR-TKIs in
NSCLCs. It has been shown that T790M-EGFR point muta-
tion increases steric hindrance at the ATP-binding region of
EGFR and inhibits the binding of EGFR-TKIs such as gefi-
tinib to EGFR members [3, 4].
Afatinib (irreversible EGFR-TKI) is useful in combination
with cetuximab (anti-EGFR mAb) on T790M-EGFR mutants
which can overcome acquired resistance induced by reversible
EGFR-TKIs. Afatinib plus cetuximab has been indicated to
induce significant regression in erlotinib-resistant NSCLC
cells with T790M in vitro. Moreover, the combination of
afatinib (40 mg/day) plus cetuximab (500 mg/m2 every
14 days) has shown good effects in a cohort of 22 NSCLC
patients with acquired resistance to gefitinib and erlotinib
[132]. In a phase I and II cohorts, 100 pretreated EGFR-
mutant patients were treated with afatinib in combination with
cetuximab. Data showed 38 and 47 % overall response rate
(ORR) in T790M mutation positive- and negative-treated pa-
tients, respectively, as well as 4.6 months of median
progression-free survival (PFS) in spite of confirmed
T790M. Currently, other trials, such as ECOG and SWOG,
are testing the efficacy of afatinib with or without cetuximab
as salvage or first-line treatment for EGFR-mutant patients
[133].
Several point mutations in HER2, such as V777L (valine to
leucine substitution at position 777), L866M (leucine to me-
thionine substitution at position 866), V842I (valine to isoleu-
cine substitution at position 842), L755S (leucine to serine
substitution at position 755), G309A/E (glycine to alanine/
glutamic acid substitution at position 309), and S310F (serine
to phenylalanine substitution at position 310), have been de-
scribed in colon and breast cancer cells. These mutations have
shown to increase the activity of signaling pathways and cell
growth. Several studies have noted that these activating mu-
tations induced resistance to anti-EGFR treatments, such as
cetuximab and panitumumab, by increasing mitogen-
activated protein kinases (MAPK)/ERK phosphorylation.
However, neratinib and afatinib (irreversible EGFR-TKIs) in-
hibit HER2 mutants in low nanomolar doses [134].
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Crizotinib, an ALK-TKI, has showed high efficacy in a
subgroup of NSCLC patients with EML4-anaplastic lympho-
ma kinase (ALK) gene rearrangement [135]. However, most
of these patients have developed acquired resistance to crizo-
tinib in 1 to 2 years after treatment. Several mechanisms have
been described to be responsible for acquired resistance to
criztinib. Alteration of the EGFR gene, EGFR-T790M muta-
tion, ALK gene mutations, such as F1174L (phenylalanine to
leucine substitution at position 1174), L1196M (leucine to
methionine substitution at position 1196), G1202R (glycine
to arginine substitution at position 1202), C1156Y (cysteine-
to-tyrosine substitution at position 1156), G1269A (glycine to
alanine substitution at position 1269), and S1206Y (serine to
tyrosine substitution at position 1206), are the mainmutations.
Other mechanisms are bypass intracellular signaling pathway
via fibroblast growth factor receptor-1 (FGFR1), AXL, and
MET overexpression [136]. Alectinib (a selective ALK-TKI)
has been used for the treatment of crizotinib-resistant patients;
however, several treated patients have developed acquired re-
sistance due to two novel ALK mutations (V1180L/valine to
leucine substitution at position 1180 and I1171T/isoleucine to
threonine substitution at position 1171) [137].
Ibrutinib is a TKI of Bruton tyrosine kinase (BTK) that
binds covalently to cysteine 481. This inhibits the SYK and
LYN autophosphorylation of the SRC homology (SH) 3 do-
main and prevents downstream activation of BCR signaling
and phospholipase Cγ2 (PLCγ2). However, acquired
ibrutinib resistance due to mutations in BTK and PLCγ2 has
been described [138]. Recently, a cysteine-to-serine mutation
in BTK (C481S) has been shown that converts ibrutinib co-
valent binding to reversible binding with the lower effect of
ibrutinib [138]. Moreover, two mutations in PLCγ2 (R665W/
arginine to tryptophan substitution at position 665 and L845F/
leucine to phenylalanine substitution at position 845) that are
gain-of-function mutations have been described to be in-
volved in ibrutinib resistance in CLL patients [138, 139].
Recently, Acalabrutinib or ACP-196 that is an irreversible
BTK inhibitor with more selectivity has been designed to
decrease the side effects of first-generation BTK inhibitors
[140]. The anti-tumor impact of this inhibitor has not been
tested in ibrutinib-resistant patients.
Hyperactivation of prosurvival signaling pathways
Hyperactivation of intracellular signaling pathways is an im-
portant mechanism of cancer drug resistance. Several path-
ways including phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR), ERK/MEK, NOTCH, WNT, forkhead box O3
(FOXO3) A, and STAT pathway hyperactivation have been
described for several tumors, such as AML and multiple
myeloma [141–147].
It has been noted that the inhibition of FLT3 by TKIs would
not inhibit the downstream signaling molecules, such as AKT,
ERK, S6K, and STAT in sorafenib-resistant AML cells with
mutations in the tyrosine kinase domain of the FLT3 [142]. In
these cells, it has been described that activation of MEK/ERK
or PI3K/AKT pathways in resistant cell lines is the main rea-
son for tolerance to sorafenib. Blocking MEK, AKT, and
mTOR by SMIs induced apoptosis of resistant cells to
sorafenib [142, 148].
In breast cancer, it has been demonstrated that overexpres-
sion of glutathione and activation of WNT signaling pathway
are the main reasons for radio-resistance of tumor cells [149].
The synergistic effects of entinostat/lapatinib combination
were described to overcome cancer resistance to lapatinib in
HER2-overexpressing tumor cells. The promising effects
were due to downregulation of AKT/FOXO3 pathway that
results in activation of Bim1 (pro-apoptotic protein) [148].
Hyperactivation of NOTCH signaling pathway has been
described in breast CSCs. Inhibition of NOTCH signaling
has been shown to increase the sensitivity of the cells to cancer
drugs [149].
Hyperactivation of other signaling molecules as STAT3
and NF-κB in glioblastoma [141] and WNT/β-catenin signal-
ing pathway have been described in different cancers that are
resistant to cancer drugs [143, 144, 150].
MicroRNAs and acquired cancer drugs resistance
miRNAs/miRs are non-coding, single-stranded RNAs that
contain 19–22 nucleotides. These short RNAs behave as reg-
ulators of signaling pathways and are important key regulators
in tumor progression [151].
Several studies have shown links between the altered ex-
pression of miRNAs and acquisition of drug resistance [152].
MiRNA deregulation in cancers has been indicated to be in-
volved in defective miRNA biogenesis pathways, deregula-
tion of gene transcription, epigenetic modifications, such as
methylation of the CpG islands, induction of mutations, and
alteration of DNA copy numbers. One or more factors may
contribute to miRNA deregulation in human cancer [153].
These molecules have dual function in cancer drug resistance
and overexpression, or downregulation is associated with both
sensitivity and resistance to cancer therapeutic drugs.
Drug resistance due to miRNA expression has been de-
scribed for several malignancies. miR-7, miR-10, miR-15a,
and miR-16 have been described to target MDR1, homeobox
D10 (HOXD10), BCL-2, and cyclin-D1 (CCND1) genes, re-
spectively, and induce resistance to cisplatin, taxol, tamoxifen,
and docetaxel in breast cancer [151]. Altered expression of
miRNA has been noted to induce chemotherapy resistance
by targeting vital signaling molecules, such as phosphatase
and tensin homolog (PTEN) and estrogen receptor (ESR) 1
in AKT, K-RAS and MAPK in PI3K/AKT signaling
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pathways, and BCL-6 and BCL-2 molecules. Moreover,
MDR1 protein, which is involved in drug resistance, has been
indicated to be deregulated by the expression of miRNAs.
Also, modification of the levels of miRNAs that target zinc
finger E-box-binding homeobox (ZEB) 1 and C-MYC mole-
cules (involved in epithelial mesenchymal transition; EMT)
have been noted in resistance of breast cancer cells to
chemotherapies.
Overexpression of miR-210 was described to be related to
the sensitivity of breast cancer cells to trastuzumab in patients
with the minimal residual disease compared to patients that
have a complete response and in patients with metastasis of
tumor cells to lymph nodes [154].
Expression of miR-34a has been indicated to sensitize
gefitinib-resistant NSCLC and HCC 827 cell lines [155].
Microarray studies demonstrated that chronic exposure of
A549 cell line with gefitinib increases the expression of 25
miRNAs and suppresses the expression of 18 others. This
difference in the expression of miRNAs has been noted to
be related to a 3-fold increase in IC50 of gefitinib. In this
study, the expression of miR-7 has been observed to abolish
the overexpression of EGFR and restored the sensitivity of
A549 cells to gefitinib [156].
Overall, current studies strongly suggest the critical role of
miRNA expression in cancer drug resistance. While some
miRNA expression is associated with drug resistance, the ex-
pression of several others has been shown to be associated
with sensitivity of tumor cells to cancer drugs. Currently, sev-
eral studies are investigating the role of miRNAs in cancer
drug resistance.
Crosstalk between intracellular signaling pathways
Crosstalk between several intracellular signaling pathways is
one of the major reasons for acquired resistance to targeted-
therapy agents [139]. BCR and receptor tyrosine kinase-like
orphan receptor 1 (ROR1) [157–163] signaling pathway
cross-communication is an example that has been recently
reported [164]. It has been noted that BCR and ROR1 control
each other expression in a manner that is vital for tumor cell
survival in ALL patients [164]. Downregulation of BCR by
the BCR-ABL TKI dasatinib (inhibits the Philadelphia chro-
mosome), as well as inactivation of AKT, inhibition of Igα
and Igβ, induced upregulation of ROR1 in leukemic cells. On
the other hand, downregulation of both ROR1 and BCR de-
phosphorylated AKT prevented cell growth and increased cell
killing. However, downregulation of ROR1 or BCR did not
induce the same effects, suggesting complementary effects.
The data also indicated an intracellular link (PI3K/AKT) be-
tween the BCR and ROR1 signaling pathways [139, 164].
Crosstalk between RTKs, such as EGFR family members,
insulin-like growth factor-I receptor (IGF-1R), VEGFR, and
MET, are known to enhance cancer progression and induction
of drug resistance [165]. The anti-HER2 mAb trastuzumab
has improved outcomes in HER2-positive breast cancer pa-
tients. However, many patients develop resistance within the
first year of treatment [166]. Activation of multiple-receptor
tyrosine kinase (RTK) signaling pathways has been indicated
to contribute to trastuzumab resistance. Similarly, a consider-
able percentage of lung or colon cancer patients do not re-
spond to anti-EGFR treatments and acquired resistance after
primary treatments [167].
Resistance of HER2-overexpressing tumors to trastuzumab
has been shown to be associated with signaling from IGF-1R
in breast cancer. Crosstalk between IGF-1R and HER2
through physical interaction of IGF1R with phosphorylates
HER2 induced acquired resistance in trastuzumab-resistant
cells; however, this interaction does not happen in
trastuzumab-sensitive tumor cells [102].
Alectinib is a selective ALK-TKI, and several studies have
indicated promising efficacy in NSCLC with EML4-ALK
gene rearrangement. However, several treated patients have
shown acquired resistance to this second generation of
ALK-TKI [137]. In addition to point mutations, other mecha-
nisms have been described for acquired resistance. By using
alectinib-resistant H3122 NSCLC cell line (H3122-AR) with
the EML4-ALK gene rearrangement, it has been described
that there is increased phosphorylation level of EGFR in
H3122-AR cells compared with H3122 [137]. Increased se-
cretion of transforming growth factor (TGF) α (EGFR ligand)
has been shown to be the reason for the hyperactivation of
EGFR. Blocking TGFα expression has been indicated to re-
store the sensitivity of H3122-AR cells to alectinib. Dual
targeting of ALK and EGFR by alectinib and afatinib has
showed to restore the sensitivity of H3122-AR cells to treat-
ment both in vitro and in a mouse xenograft model [137].
Overall, the complication of tumor cells signaling suggests
the requirement of targeting several RTKs for efficient cancer
therapeutics.
Chronopharmacology and resistance to targeted therapies
Chronopharmacology is the study of the effects and behavior
of therapeutic agents during the biological timing and endog-
enous factors. The goal of chronopharmacology is to increase
the understanding of periodic and predictable changes in the
effects and tolerance of drugs in tumor patients (in the field of
tumor treatment) [168, 169]. Several studies have described
that anti-tumor effect of cancer drugs differs at the time of day
of administration, and it might be a clinically important factor
in cancer-treated patients that may prevent drug resistance
[170].
The impacts of timing on the anti-tumor effects of erlotinib
have been investigated in the mouse model of Lewis lung cancer
xenografts [170]. Results proposed that anti-tumor efficacy and
toxicity of erlotinib on xenografts of NSCLC mice model is
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dependent on the time of day of administration. The effects may
be associated with the EGFR-AKT/cyclin D1/cyclin-dependent
kinase (CDK) 4 signaling pathway and might be a clinically
important variable [170]. The association of chronopharmacology
factors with cancer drug resistance has not been well studied, and
more investigations are necessary to explore the effects for preven-
tion of drug resistance.
Conclusions and future prospective
Current data indicate that most or all patients with cancer develop
resistance to different types of treatments, including chemother-
apy and targeted-therapy regimens. The resistance to cancer
drugs is due to the combination of several complicated factors,
including pharmacokinetic and pharmacodynamic mechanisms.
These factors that are involved in drug resistance might be due to
primary reasons that developed in the absence of drugs or are
secondary due to the drug effects. Therefore, a better understand-
ing of tumor cell biology andmechanism of tumor cell resistance
to therapies is necessary to define proper strategies and avoid
drug resistance. To prevent drug resistance, several strategies,
such as targeting various molecules that are expressed by tumors
(multiple-targeted therapy) using SMIs and mAbs and combina-
tion therapy, such as SMI combination with immunotherapy
methods, and targeting CSCs or optimizing the methods of
intra-tumoral drug delivery as well as a defined treatment guide-
line for each cancer, might be necessary to prevent drug resis-
tance and cancer recurrence. CSCs are highly resistant to cancer
drugs and very likely cause disease relapse. Specific targeting of
these cells is amajor obstacle to cancer treatment. Overwhelming
this problem in different cancers is important; however, difficult-
to-achieve. Moreover, a better understanding of bone marrow
microenvironment, mechanisms of overactivation of survival
signaling pathways by tumor cells and CSCs, and cell-to-cell
interaction of tumor cells with supporting cells are important
factors for defeating cancer. On the other hand, current drugs
might not be effective in cancer treatment and new modalities
with more potential effects on both CSCs and tumor cells are
essential.
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